Evidence map›Paper›PMID 37406053›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Antibiotic Consumption During the Coronavirus Disease 2019 Pandemic and Emergence of Carbapenemase-Producing Klebsiella pneumoniae Lineages Among Inpatients in a Chilean Hospital: A Time-Series Study and Phylogenomic Analysis.

Kasim Allel, Anne Peters, José Conejeros, José R W Martínez, Maria Spencer-Sandino, Roberto Riquelme-Neira, Lina Rivas, Pamela Rojas, Cristian Orellana Chea, Patricia García and 7 more

Open access · hybridAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Dynamics of clinicalApplied and environmental microbiology · 2026
    Article
  4. Article
  5. Article
  6. Epidemiological Insights into Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026
    Article
  7. Review
  8. Article
  9. Clinical characterization of anFrontiers in cellular and infection microbiology · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Article
  18. Emerging carbapenem-resistantMicrobiology spectrum · 2025
    Article
  19. Multispecies emergence of dualAntimicrobial agents and chemotherapy · 2025
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 4 countries.

Kasim AllelDepartment of Disease Control, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Anne PetersMultidisciplinary Initiative for Collaborative Research On Bacterial Resistance (MICROB-R), Santiago, Chile.
José ConejerosMultidisciplinary Initiative for Collaborative Research On Bacterial Resistance (MICROB-R), Santiago, Chile.
José R W MartínezMultidisciplinary Initiative for Collaborative Research On Bacterial Resistance (MICROB-R), Santiago, Chile.
Maria Spencer-SandinoMultidisciplinary Initiative for Collaborative Research On Bacterial Resistance (MICROB-R), Santiago, Chile.
Roberto Riquelme-NeiraMultidisciplinary Initiative for Collaborative Research On Bacterial Resistance (MICROB-R), Santiago, Chile.
Lina RivasMultidisciplinary Initiative for Collaborative Research On Bacterial Resistance (MICROB-R), Santiago, Chile.
Pamela RojasHospital Padre Hurtado, Santiago, Chile.
Cristian Orellana CheaHospital Padre Hurtado, Santiago, Chile.
Patricia GarcíaMultidisciplinary Initiative for Collaborative Research On Bacterial Resistance (MICROB-R), Santiago, Chile.
Rafael AraosMultidisciplinary Initiative for Collaborative Research On Bacterial Resistance (MICROB-R), Santiago, Chile.
Olivia McGovernDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Twisha S PatelDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Cesar A AriasDivision of Infectious Diseases, Houston Methodist Hospital, Texas, USA.
Fernanda C LessaDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Eduardo A UndurragaMultidisciplinary Initiative for Collaborative Research On Bacterial Resistance (MICROB-R), Santiago, Chile.
José M MunitaMultidisciplinary Initiative for Collaborative Research On Bacterial Resistance (MICROB-R), Santiago, Chile.
Universidad del Desarrollo · CLCenters for Disease Control and Prevention · USClínica Alemana · CLMillennium Initiative for Collaborative Research on Bacterial Resistance · CLHospital Padre Hurtado · CLMethodist Hospital · USUniversity College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe impact of coronavirus disease 2019 (COVID-19) on antimicrobial use (AU) and resistance has not been well evaluated in South America. These data are critical to inform national policies and clinical care.

methodsAt a tertiary hospital in Santiago, Chile, between 2018 and 2022, subdivided into pre- (3/2018-2/2020) and post-COVID-19 onset (3/2020-2/2022), we evaluated intravenous AU and frequency of carbapenem-resistant Enterobacterales (CRE). We grouped monthly AU (defined daily doses [DDD]/1000 patient-days) into broad-spectrum β-lactams, carbapenems, and colistin and used interrupted time-series analysis to compare AU during pre- and post-pandemic onset. We studied the frequency of carbapenemase-producing (CP) CRE and performed whole-genome sequencing analyses of all carbapenem-resistant (CR) Klebsiella pneumoniae (CRKpn) isolates collected during the study period.

resultsCompared with pre-pandemic, AU (DDD/1000 patient-days) significantly increased after the pandemic onset, from 78.1 to 142.5 (P < .001), 50.9 to 110.1 (P < .001), and 4.1 to 13.3 (P < .001) for broad-spectrum β-lactams, carbapenems, and colistin, respectively. The frequency of CP-CRE increased from 12.8% pre-COVID-19 to 51.9% after pandemic onset (P < .001). The most frequent CRE species in both periods was CRKpn (79.5% and 76.5%, respectively). The expansion of CP-CRE harboring blaNDM was particularly noticeable, increasing from 40% (n = 4/10) before to 73.6% (n = 39/53) after pandemic onset (P < .001). Our phylogenomic analyses revealed the emergence of two distinct genomic lineages of CP-CRKpn: ST45, harboring blaNDM, and ST1161, which carried blaKPC.

conclusionsAU and the frequency of CP-CRE increased after COVID-19 onset. The increase in CP-CRKpn was driven by the emergence of novel genomic lineages. Our observations highlight the need to strengthen infection prevention and control and antimicrobial stewardship efforts.

Indexed as

Anti-Infective AgentsCarbapenem-Resistant EnterobacteriaceaeCOVID-19Anti-Bacterial AgentsBacterial Proteinsbeta-Lactamasesbeta-LactamsCarbapenemsChileColistinHospitalsHumansInpatientsKlebsiella pneumoniaeMicrobial Sensitivity TestsPandemicsAnti-Bacterial AgentsAnti-Infective AgentsBacterial Proteinsbeta-Lactamasesbeta-LactamscarbapenemaseCarbapenemsColistinAntibiotic consumptionAntimicrobial resistanceCarbapenemase-producing organismsCOVID-19

Identifiers

PMID37406053
PMCPMC10321701
OpenAlexW4383198258

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.